Institute of Cardiovascular and Medical Sciences

Dr Jo Mountford

  • Senior Lecturer (Institute of Cardiovascular and Medical Sciences)
  • Adviser Of Studies (School of Life Sciences Administration)

telephone: 01413307212
email: Jo.Mountford@glasgow.ac.uk


Jump to: 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2003
Number of items: 32.

2013

Lindsay, S.L., Johnstone, S.A., Mountford, J.C., Sheikh, S., Allan, D.B., Clark, L., and Barnett, S.C. (2013) Human mesenchymal stem cells isolated from olfactory biopsies but not bone enhance CNS myelinationin vitro. Glia, 61 (3). pp. 368-382. ISSN 0894-1491 (doi:10.1002/glia.22440)

2012

Kaupisch, A., Kennedy, L., Stelmanis, V., Tye, B., Kane, N.M., Mountford, J.C., Courtney, A., and Baker, A.H. (2012) Derivation of vascular endothelial cells from human embryonic stem cells under GMP-compliant conditions: towards clinical studies in ischaemic disease. Journal of Cardiovascular Translational Research, 5 (5). pp. 605-617. ISSN 1937-5387 (doi:10.1007/s12265-012-9379-2)

Marenah, L., Allan, E.K., Mountford, J.C., Holyoake, T.L., Jorgensen, H.G., and Elliott, M.A. (2012) Investigation into omacetaxine solution stability for in vitro study. Biomedical Chromatography, 26 (5). pp. 545-547. ISSN 0269-3879 (doi:10.1002/bmc.1686)

Kane, N.M. et al. (2012) Role of MicroRNAs 99b, 181a, and 181b in the differentiation of human embryonic stem cells to vascular endothelial cells. Stem Cells, 30 (4). pp. 643-654. ISSN 1066-5099 (doi:10.1002/stem.1026)

Terrin, A. et al. (2012) PKA and PDE4D3 anchoring to AKAP9 provides distinct regulation of cAMP signals at the centrosome. Journal of Cell Biology, 198 (4). pp. 607-621. ISSN 0021-9525 (doi:10.1083/jcb.201201059)

2011

Mountford, J.C., and Turner, M. (2011) In vitro production of red blood cells. Transfusion and Apheresis Science, 45 (1). pp. 85-89. ISSN 1473-0502 (doi:10.1016/j.transci.2011.06.007)

Marenah, L., Allan, E.K., Mountford, J.C., Holyoake, T.L., Jorgensen, H.J., and Elliott, M.A. (2011) Investigation into omacetaxine solution stability for in vitro study. Biomedical Chromatography, 26 (5). pp. 545-547. ISSN 0269-3879 (doi:10.1002/bmc.1686)

Mountford, J.C., and Turner, M. (2011) In vitro production of red blood cells. Transfusion and Apheresis Science, 45 (1). pp. 85-89. ISSN 1473-0502 (doi:10.1016/j.transci.2011.06.007)

Yung, S. et al. (2011) Large-scale transcriptional profiling and functional assays reveal important roles for Rho-GTPase signalling and SCL during haematopoietic differentiation of human embryonic stem cells. Human Molecular Genetics, 20 (24). pp. 4932-4946. ISSN 0964-6906 (doi:10.1093/hmg/ddr431)

2010

Burton, P. et al. (2010) Identification and characterization of small-molecule ligands that maintain pluripotency of human embryonic stem cells. Biochemical Society Transactions, 38 (4). pp. 1058-1061. ISSN 0300-5127 (doi:10.1042/BST0381058)

Kane, N.M., Meloni, M., Spencer, H.L., Craig, M.A., Strehl, R., Milligan, G., Houslay, M.D., Mountford, J.C., Emanueli, C., and Baker, A.H. (2010) Derivation of endothelial cells from human embryonic stem cells by directed differentiation: analysis of microRNA and angiogenesis in vitro and in vivo. Arteriosclerosis, Thrombosis and Vascular Biology, 30 (7). pp. 1389-1397. ISSN 1079-5642 (doi:10.1161/ATVBAHA.110.204800)

Mountford, J.C., Olivier, E., and Turner, M. (2010) Prospects for the manufacture of red cells for transfusion. British Journal of Haematology, 149 (1). pp. 22-34. ISSN 0007-1048 (doi:10.1111/j.1365-2141.2010.08079.x)

Andrews, Paul et al. (2010) High content screening of feeder-free human embryonic stem cells to identify pro-survival small molecules. Biochemical Journal, 432 (Pt 1). pp. 21-33. ISSN 0264-6021 (doi:10.1042/BJ20101022)

Burton, P. et al. (2010) Erythro-9-(2-hydroxy-3-nonyl)adenine (EHNA) blocks differentiation and maintains the expression of pluripotency markers in human embryonic stem cells. Biochemical Journal, 432 (3). pp. 575-584. ISSN 0264-6021 (doi:10.1042/BJ20100726)

Burton, Peter et al. (2010) Identification and characterization of small-molecule ligands that maintain pluripotency of human embryonic stem cells. Biochemical Society Transactions, 38 (4). pp. 1058-1061. ISSN 0300-5127 (doi:10.1042/BST0381058)

Kane, N.M. et al. (2010) Lentivirus-mediated reprogramming of somatic cells in the absence of transgenic transcription factors. Molecular Therapy, 18 (12). pp. 2139-2145. ISSN 1525-0016 (doi:10.1038/mt.2010.231)

Mountford, J.C., Olivier, Emmanuel, Jordanides, Niove E, de Sousa, Paul, and Turner, Marc L (2010) Red blood cells from pluripotent stem cells for use in transfusion. Regenerative Medicine, 5 (3). pp. 411-423. ISSN 1746-0751 (doi:10.2217/rme.10.22)

2009

Pellicano, F., Copland, M., Jorgensen, H.G., Mountford, J., Leber, B., and Holyoake, T. (2009) BMS-214662 induces mitochondrial apoptosis in chronic myeloid leukemia (CML) stem/progenitor cells, including CD34+38- cells, through activation of protein kinase Cβ. Blood, 114 (19). pp. 4186-4196. ISSN 0006-4971 (doi:10.1182/blood-2009-05-219550 )

Davies, A. et al. (2009) Nilotinib concentration in cell lines and primary CD34+ chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters. Leukemia, 23 (11). pp. 1999-2006. ISSN 0887-6924 (doi:10.1038/leu.2009.166)

Hatziieremia, S., Jordanides, N.E., Holyoake, T.L., Mountford, J.C., and Jorgensen, H.G. (2009) Inhibition of MDR1 does not sensitize primitive chronic myeloid leukemia CD34+ cells to imatinib. Experimental Hematology, 37 (6). pp. 692-700. ISSN 0301-472X (doi:10.1016/j.exphem.2009.02.006 )

Khanim, F.L. et al. (2009) Combined bezafibrate and medroxyprogesterone acetate: potential novel therapy for acute myeloid leukaemia. PLoS ONE, 4 (12). e8147. ISSN 1932-6203 (doi:10.1371/journal.pone.0008147)

Myssina, S. et al. (2009) Combined BCR-ABL inhibition with lentiviral-delivered shRNA and dasatinib augments induction of apoptosis in Philadelphia-positive cells. Experimental Hematology, 37 (2). pp. 206-214. ISSN 0301-472X (doi:10.1016/j.exphem.2008.10.013 )

2008

Mountford, J.C. (2008) Human embryonic stem cells: origins, characteristics and potential for regenerative therapy. Transfusion Medicine, 18 (1). pp. 1-12. ISSN 0958-7578 (doi:10.1111/j.1365-3148.2007.00807.x)

2007

Strathdee, G. et al. (2007) Inactivation of HOXA genes by hypermethylation in myeloid and lymphoid malignancy is frequent and associated with poor prognosis. Clinical Cancer Research, 13 (17). pp. 5048-5055. ISSN 1078-0432 (doi:10.1158/1078-0432.CCR-07-0919)

Allan, E.K., Holyoake, T.L., Jordanides, N.E., Jorgensen, H.G., and Mountford, J.C. (2007) Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells. Blood, 109 (9). pp. 4016-4019. ISSN 0006-4971 (doi:10.1182/blood-2006-11-057521)

2006

Holyoake, T.L., Jordanides, N., Jorgensen, H.G., and Mountford, J.C. (2006) Functional ABCG2 is overexpressed on primary CML CD34+ cells and is inhibited by imatinib mesylate. Blood, 108 (4). pp. 1370-1373. ISSN 0006-4971 (doi:10.1182/blood-2006-02-003145)

Copland, M, Hamilton, A, Eirick, LJ, Baird, JW, Allan, EK, Jordanides, N, Barow, M, Mountford, JC, and Holyoake, TL (2006) Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood, 107 (11). pp. 4532-4539. ISSN 0006-4971 (doi:10.1182/blood-2005-07-2947)

2005

Jorgensen, H.G., Allan, E.K., Mountford, J.C., Richmond, L., Harrison, S., Elliott, M.A., and Holyoake, T.L. (2005) Enhanced CML stem cell elimination in vitro by bryostatin priming with imatinib mesylate. Experimental Hematology, 33 (10). pp. 1140-1146. ISSN 0301-472X (doi:10.1016/j.exphem.2005.05.020)

Allan, E.K., Eaves, C.J., Elliott, M.A., Godden, J.L., Graham, S.M., Holyoake, T.L., Jorgensen, H.G., Mountford, J.C., and Richmond, L. (2005) Lonafarnib reduces the resistance of primitive quiescent CML cells to imatinib mesylate in vitro. Leukemia, 19 (7). pp. 1184-1191. ISSN 0887-6924 (doi:10.1038/sj.leu.2403785)

Elrick, L.J., Holyoake, T.L., Jorgensen, H.G., and Mountford, J.C. (2005) Punish the parent not the progeny. Blood, 105 (5). pp. 1862-1866. ISSN 0006-4971 (doi:10.1182/blood-2004-08-3373)

Bunce, CM, Hayden, RE, Mountford, JC, and Vanin, EF (2005) All-trans retinoic acid increases transgene expression in MSCV-transduced cells, via a mechanism that is retinoid receptor dependent but independent of cellular differentiation. Human Gene Therapy, 16 . pp. 132-138.

2003

Clark, A.D., Jorgensen, H.G., Mountford, J.C., and Holyoake, T.L. (2003) Isolation and therapeutic potential of human haemopoietic stem cells. Cytotechnology, 41 (2-3). pp. 111-131. ISSN 0920-9069 (doi:10.1023/A:1024822722285)

This list was generated on Thu May 2 14:43:19 2013 BST.

Grants and Awards listed are those received whilst working with the University of Glasgow.

  • Proof of principle: Human embryonic stem cell derived red cell concentrates for clinical transfusion
    Wellcome Trust
    2013 - 2013
     
  • TRANSLATING HUMAN EMBRYONIC STEM CELL-DERIVED ENDOTHELIAL CELL THERAPY TO THE CLINIC
    Medical Research Council
    2012 - 2015
     
  • Characterisation of T16, a novel stem cell survival compound (ISSF Catalyst Fund)
    Wellcome Trust
    2011 - 2014
     
  • Red blood cell programme
    Scottish Funding Council
    2011 - 2011
     
  • Red blood cell programme
    Scottish Funding Council
    2011 - 2011
     
  • In vitro and in vivo analysis of stem cell commitment to vascular endothelial cells
    British Heart Foundation
    2011 - 2013
     
  • miRNA study with Sistemic
    Scottish Enterprise Glasgow
    2010 - 2011
     
  • Clinical translation of endothelial cells derived from human embryonic stem cells
    Technology Strategy Board
    2010 - 2011
     
  • Proof of principle: Human embryonic stem cell derived red cell concentrates for clinical transfusion
    Wellcome Trust
    2009 - 2013
     
  • Production of cardiomyocytes from human embryonic stem cells
    Stem Cells for Safer Medicines
    2009 - 2010
     
  • Effect of major efflux transporters on the intracellular concentration of dasatinib in CML CD34+ patient cells and cell lines
    Tenovus-Scotland
    2009 - 2009
     
  • Measurement and modulation of tyrosine kinase inhibitor drug levels in chronic myeloid leukaemia.
    Scottish Executive Health Department
    2007 - 2008
     
  • Generation of Cardiomyocytes from Mesenchymal Stem Cells derived from Adult Human Bone Marrow
    British Heart Foundation
    2005 - 2007
     
  • Do transporter proteins contribute to clinical resistance to imatinib in chronic myeloid leukaemia? A combined study in Liverpool and Glasgow, correlating transporter expression and function with Imatinib uptake and efflux.
    Leukaemia Research Fund
    2004 - 2007
     
  • Novel drug combinations for eradication of Ph+/Bcr-Abl+ haemopoietic stem cells in chronic myeloid leukaemia (CML)
    MRC
    2003 - 2006
     
  • Novel drug combinations for eradication of Ph+/Bcr-Abl+ haemopoietic stem cells in chronic myeloid leukaemia (CML)
    Leukaemia Research Trust for Scotland
    2003 - 2006
     
  • Collection of normal cord blood cells as control samples. (b) Characterisation and expansion of haemopoietic stem cells from umbilical cor.
    Scottish National Blood Transfusion Service
    2003 - 2006
     
  • Collection of normal cord blood cells as control samples. (a) Development of new treatment regimes for leukaemia: specificity of drug ef
    MRC
    2003 - 2006
     

Grant Advisory Board

  • 2006 - ongoing: Scottish Stem Cell Network - Advisory Board Member

Invited International Presentations

  • 2008: Heriot-Watt University, Edinburgh, Scotland, UK - Invited Speaker: British Association for Gene Therapy, Public Open Day, Journeys in the Genetic Jungle.
  • 2008: Heriot-Watt University, Edinburgh, Scotland, UK - Invited Speaker: UK Nation Stem Cell Network Annual Meeting
  • 2007: Imperial College, London, UK - Invited Speaker: Drug Resistance Annual Workshop
  • 2007: Dundee, Scotland, UK - Chair: BBSRC Public Debate. Stem Cell Science - 'Hope not Hype.'
  • 2007: Giens, France - Plenary Speaker: Club Hématopoïèse et Oncogenèse (CHO) Stem Cells and Cancer Meeting
  • 2007: Singapore - Plenary Speaker: AACR Centennial Conference. Translational Cancer Medicine: Technologies to Therapy
  • 2006: Erasmus University, Rotterdam, Netherlands - Invited Speaker: Basic and Translational Oncology 2006
  • 2006: Imperial College, London, UK - Invited Speaker: Dept of Haematology
  • 2005: Glasgow, Scotland, UK - Session Chair: Mesenchymal Stem Cell Biology. ISEH
  • 2005: Fettes College, Edinburgh, Scotland, UK - Invited Speaker: StemCell2005 Conference Schools Event
  • 2005: Birkbeck College, London, UK - Invited Speaker: EuroSciCon, Growth, Expansion and Differentiation of Stem Cells
  • 2005: Glasgow, Scotland, UK - Invited Speaker: Novartis Satellite Symposium, Leading the way in CML. ISEH,
  • 2004: Canada - Invited Participant: Leukemia & Lymphoma Society Special Workshop on Cancer Stem Cells (Closed meeting).
  • 2004: ASH San Diego, USA - Oral Presentation: Simultaneous Session, Abstr 716, Functional ABCG2 Is Expressed on CML Stem Cells and Its Inhibition Selectively Depletes CML CD34+ Cells.
  • 2004: Cyprus - Session Chair: BACR Workshop on Cancer Stem Cells and Telomerase.

Professional Learned Society

  • 2006 - ongoing: International Society for Stem Cell Research - Member
  • 2005 - ongoing: American Society of Hematology - Full International Member
  • 2005 - ongoing: European Hematology Association - Member
  • 2005 - ongoing: British Society for Hematology - Member

Research Fellowship

  • 2001 - 2002: Lemuel W Diggs Fellow in Experimental Hematology
  • 1997 - 2001: Barling-Radcliffe Prize Research Fellow